
Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results. The …

Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …

GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 …

Ian Campbell has been named by Innovate UK as its first director for Health and Life Sciences. Innovate UK is …

The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …

Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …

Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …

Global pharmaceutical company Allergan has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of …

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …

AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …

Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …
A battle is raging for the soul of the pharma industry and the stakes are high. Those companies seeking to …

Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …

Following an FDA inspection and WHO investigation earlier this year, the European Medicines Agency (EMA) has recommended the suspension of …

Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …

AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …

Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …

Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …

The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …